Central Serous Retinopathy

Central serous retinopathy may cause one eye to seem dimmer, straight edges to look distorted, or the center of vision to appear gray or blurred. In central serous retinopathy, also called central serous chorioretinopathy (CSCR), fluid leaks under the macula through the retinal pigment epithelium (RPE). Many acute episodes resolve over a few months. Chronic or recurrent fluid requires closer management because persistent subretinal fluid can damage the macula.

Overview

Central serous retinopathy is a relatively common condition that tends to affect young to middle-aged adults, particularly men. Many first-time acute cases improve substantially, but recovery varies. Chronic or frequently recurring CSR can leave RPE damage, distortion, contrast loss, persistent fluid, or other lasting visual symptoms.

Symptoms

• Blurred vision in one eye (usually)
• Distorted vision (metamorphopsia) - straight lines appear bent
• Central dark or dim spot
• Objects appear smaller than normal (micropsia) in the affected eye
• Colors may appear washed out or duller in the affected eye
• Reduced contrast sensitivity
• May be asymptomatic if the fluid is not directly under the fovea

Causes and Risk Factors

The Mechanism

The retinal pigment epithelium (RPE) normally acts as a barrier, keeping fluid from the choroid (blood vessel layer) away from the retina. In CSR, this barrier breaks down at one or more points, allowing fluid to seep under the retina.

Major Risk Factors

• Stress and "type A" personality - the classic association
• Corticosteroid use - the strongest modifiable risk factor
  • Oral prednisone
  • Inhaled steroids (for asthma)
  • Nasal steroid sprays
  • Steroid creams (even on distant skin)
  • Steroid joint injections
• Male sex (6:1 male-to-female ratio)
• Age 30-50
• Pregnancy (often improves after delivery)
• Obstructive sleep apnea
• Helicobacter pylori infection (association reported)
• Organ transplant (due to chronic steroid/immunosuppressive use)

Diagnosis

• Optical coherence tomography (OCT) - clearly shows the dome of subretinal fluid under the macula; essential for diagnosis and monitoring
• Fluorescein angiography - shows the point of leakage (classic "smokestack" or "inkblot" pattern); helps guide laser treatment if needed
• Indocyanine green (ICG) angiography - evaluates the choroidal blood flow; helpful in chronic cases
• Fundus autofluorescence - detects RPE changes, especially in chronic CSR
• Visual acuity testing - typically 20/20 to 20/40 in acute cases

Treatment

Acute CSR

Observation (first-line):

• Most acute episodes resolve spontaneously in 3-4 months
• Ask about reducing or stopping corticosteroids when the prescribing clinician says it is safe; steroid exposure is often an important modifiable factor
• Reduce stress - exercise, sleep, relaxation techniques
• Treat sleep apnea if present
• Monitor with monthly OCT

Chronic or Recurrent CSR

If fluid persists beyond 4-6 months or vision deteriorates:

Photodynamic therapy (PDT):

• One of the best-supported treatments for selected chronic or persistent CSR
• Low-fluence (half-dose) PDT is preferred to minimize side effects
• Targets the abnormal choroidal vessels causing the leak
• Fluid resolution is common in selected cases, but visual recovery varies

Focal laser photocoagulation:

• Applied directly to the leakage point
• Only used when the leak is well away from the foveal center
• Quick and effective but can create a small blind spot

Anti-VEGF injections:

• Less effective than PDT for typical CSR
• May be used in combination with PDT
• More helpful when there is associated choroidal neovascularization

Mineralocorticoid antagonists (oral):

• Eplerenone or spironolactone
• Earlier small studies suggested possible benefit, but the VICI trial found eplerenone was not superior to placebo
• Not routinely recommended as first-line therapy; PDT has stronger evidence when chronic CSR requires treatment

Prognosis

Acute CSR

• Many first-time acute cases improve substantially within 3-4 months
• Vision often improves, but full recovery is not guaranteed
• Subtle changes in color perception or contrast may persist
• Recurrence rate: 30-50% over subsequent years

Chronic CSR

• More guarded - prolonged fluid causes progressive RPE and photoreceptor damage
• Treatment can resolve fluid but some visual changes may be permanent
• Long-term monitoring is important

When to See a Doctor

Frequently Asked Questions

Will CSR go away on its own?

Most acute episodes do resolve spontaneously within 3-4 months. However, chronic cases lasting longer than 4-6 months usually require treatment to prevent permanent retinal damage.

Can stress really cause an eye problem?

CSR has a well-recognized association with stress physiology and steroid exposure, though not all cases are stress-caused. The mechanism likely involves stress hormones (cortisol) affecting the choroidal blood vessels and RPE barrier. Stress reduction can be a useful part of management.

How long should I wait before getting treatment?

For a first episode with good visual acuity, most ophthalmologists recommend observing for 3-4 months. If fluid is still present, the vision is significantly affected, or you've had multiple recurrences, earlier treatment may be appropriate.

Can I prevent recurrences?

Avoiding corticosteroids, managing stress, treating sleep apnea, and maintaining overall health can reduce recurrence risk. However, some patients have recurrences despite these measures.

Is CSR related to macular degeneration?

CSR and macular degeneration are different conditions. However, chronic CSR can sometimes be confused with certain forms of macular degeneration, and long-standing CSR can cause retinal changes resembling those of macular degeneration. Your ophthalmologist can distinguish between them.

References